Evaluation of Bactec mycosis IC/F and plus aerobic/f blood culture bottles for detection of Candida in the presence of antifungal agents

Journal of Clinical Microbiology

Volumn 51, Issue 11, 2013, Pages 3683-3687

  Köck, Robin ^a   Eibing, Lea C ^a   Boschin, Matthias G ^a   Ellger, Björn ^a   Horn, Dagmar ^a   Idelevich, Evgeny A ^a   Becker, Karsten ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; DIFLUCAN IV; FLUCONAZOLE; MICAFUNGIN; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BACTEC MYCOSIS IC F CULTURE BOTTLE; BACTEC PLUS AEROBIC F CULTURE BOTTLE; BLOOD CULTURE; CANDIDA ALBICANS; CANDIDA GLABRATA; CLINICAL PRACTICE; COLONY FORMING UNIT; COMPARATIVE STUDY; CONTAINER; CONTROLLED STUDY; DIFFUSION COEFFICIENT; FUNGUS CULTURE; GLASS BOTTLE; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDEMIA; DRUG MONITORING; HUMANS; MICROBIOLOGICAL TECHNIQUES; TIME FACTORS;

EID: 84886462677     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02048-13     Document Type: Article

References (25)

1. Kett DH, Azoulay E, Echeverria PM, Vincent JL. 2011. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit. Care Med. 39:665-670.
2. Schmalreck AF, Willinger B, Haase G, Blum G, Lass-Florl C, Fegeler W, Becker K. 2012. Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi-centre study. Mycoses 55:e124-e137. doi:10.1111/j.1439 -0507.2011.02165.x.
3. Pfaller MA, Diekema DJ. 2004. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin. Microbiol. Infect. 10:11-23.
4. Chiarini A, Palmeri A, Amato T, Immordino R, Distefano S, Giammanco A. 2008. Detection of bacterial and yeast species with the Bactec 9120 automated system with routine use of aerobic, anaerobic, and fungal media. J. Clin. Microbiol. 46:4029-4033.
5. Fricker-Hidalgo H, Chazot F, Lebeau B, Pelloux H, Ambroise-Thomas P, Grillot R. 1998. Use of simulated blood cultures to compare a specific fungal medium with a standard microorganism medium for yeast detection. Eur. J. Clin. Microbiol. Infect. Dis. 17:113-116.
6. Meyer MH, Letscher-Bru V, Jaulhac B, Waller J, Candolfi E. 2004. Comparison of Mycosis IC/F and plus Aerobic/F media for diagnosis of fungemia by the Bactec 9240 system. J. Clin. Microbiol. 42:773-777.
7. Ericson EL, Klingspor L, Ullberg M, Ozenci V. 2012. Clinical comparison of the Bactec Mycosis IC/F, BacT/Alert FA, and BacT/Alert FN blood culture vials for the detection of candidemia. Diagn. Microbiol. Infect. Dis. 73:153-156.
8. Klingspor L, Muhammed SA, Ozenci V. 2012. Comparison of the two blood culture systems, Bactec 9240 and BacT/Alert 3D, in the detection of Candida spp. and bacteria with polymicrobial sepsis. Eur. J. Clin. Microbiol. Infect. Dis. 31:2983-2987.
9. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
10. Kullberg BJ, Verweij PE, Akova M, Arendrup MC, Bille J, Calandra T, Cuenca-Estrella M, Herbrecht R, Jacobs F, Kalin M, Kibbler CC, Lortholary O, Martino P, Meis JF, Munoz P, Odds FC, De Pauw BE, Rex JH, Roilides E, Rogers TR, Ruhnke M, Ullmann AJ, Uzun O, Vandewoude K, Vincent JL, Donnelly JP. 2011. European expert opinion on the management of invasive candidiasis in adults. Clin. Microbiol. Infect. 17(Suppl 5):1-12.
11. Benson JM, Nahata MC. 1989. Pharmacokinetics of amphotericin B in children. Antimicrob. Agents Chemother. 33:1989-1993.
12. GraysonM(ed). 2010. Kucers' the use of antibiotics, 6th ed, vol 1. Edward Arnold Publishers Ltd., London, England.
13. Stone JA, Holland SD, Wickersham PJ, Sterrett A, Schwartz M, Bonfiglio C, Hesney M, Winchell GA, Deutsch PJ, Greenberg H, Hunt TL, Waldman SA. 2002. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob. Agents Chemother. 46:739-745.
14. Foulds G, Wajszczuk C, Weidler DJ, Garg DJ, Gibson P. 1988. Steady state parenteral kinetics of fluconazole in man. Ann. N. Y. Acad. Sci. 544: 427-430.
15. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. 2002. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob. Agents Chemother. 46:2546-2553.
16. Pfeiffer CD, Samsa GP, Schell WA, Reller LB, Perfect JR, Alexander BD. 2011. Quantitation of Candida CFU in initial positive blood cultures. J. Clin. Microbiol. 49:2879-2883.
17. Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, Vazquez JA, Dupont BF, Horn DL, Ostrosky-Zeichner L, Reboli AC, Suh B, Digumarti R, Wu C, Kovanda LL, Arnold LJ, Buell DN. 2007. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin. Infect. Dis. 45:883-893.
18. Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, Washburn RG, Scheld WM, Karchmer AW, Dine AP, Candidemia Study Group and the National Institute. 1994. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N. Engl. J. Med. 331:1325-1330.
19. Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards JE, Hadley S, Brass C, Vazquez JA, Chapman SW, Horowitz HW, Zervos M, McKinsey D, Lee J, Babinchak T, Bradsher RW, Cleary JD, Cohen DM, Danziger L, Goldman M, Goodman J, Hilton E, Hyslop NE, Kett DH, Lutz J, Rubin RH, Scheld WM, Schuster M, Simmons B, Stein DK, Washburn RG, Mautner L, Chu TC, Panzer H, Rosenstein RB, Booth J. 2003. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin. Infect. Dis. 36:1221-1228.
20. Spaargaren J, van Boven CP, Voorn GP. 1998. Effectiveness of resins in neutralizing antibiotic activities in Bactec plus Aerobic/F culture medium. J. Clin. Microbiol. 36:3731-3733.
21. Lelièvre H, Gimenez M, Vandenesch F, Reinhardt A, Lenhardt D, Just HM, Pau M, Ausina V, Etienne J. 1997. Multicenter clinical comparison of resin-containing bottles with standard aerobic and anaerobic bottles for culture of microorganisms from blood. Eur. J. Clin. Microbiol. Infect. Dis. 16:669-674.
22. Chen SC, Slavin MA, Sorrell TC. 2011. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs 71:11-41.
23. Li Y, Nguyen MH, Cheng S, Schmidt S, Zhong L, Derendorf H, Clancy CJ. 2008. A pharmacokinetic/pharmacodynamic mathematical model accurately describes the activity of voriconazole against Candida spp. in vitro. Int. J. Antimicrob. Agents 31:369-374.
24. Liu P, Ruhnke M, Meersseman W, Paiva JA, Kantecki M, Damle B. 2013. Pharmacokinetics of anidulafungin in critically ill patients with candidemia/ invasive candidiasis. Antimicrob. Agents Chemother. 57:1672-1676.
25. Oshima K, Kanda Y, Kako S, Ohno K, Kishino S, Kurokawa M. 2013. Pharmacokinetics of micafungin in patients undergoing allogeneic hematopoietic stem cell transplantation. Transpl. Infect. Dis. 15:323-327